PCOS is Now PMOS: Understanding the Landmark Rename and What It Means for Your Fertility Health

By Dr. Puneet Rana Arora Founder & Director, CIFAR — Centre for Infertility & Assisted Reproduction, Gurugram FRCOG (Royal College of Obstetricians & Gynaecologists, UK) | MSc Reproduction & Development, University of Bristol, UK

For decades, millions of women have lived with a diagnosis whose very name misrepresented the condition they were battling. In May 2026, the global medical community took a decisive and long-overdue step: Polycystic Ovary Syndrome (PCOS) was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS).

As a fertility specialist and reproductive medicine expert with over 25 years of clinical experience — including a decade within the UK’s National Health Services — I have seen first-hand how the old terminology led to delayed diagnoses, fragmented treatment, and unnecessary emotional burden for countless women. At CIFAR, we welcome this change wholeheartedly. This article explains the science behind the renaming, what PMOS truly is, and what this means for women seeking fertility care.

Why Was the Name Changed?

The name change was not cosmetic. It was the outcome of an unprecedented, decade-long global consensus process led by Professor Helena Teede of Monash University, Australia, published in The Lancet and endorsed by over 56 leading academic, clinical, and patient organisations worldwide — including the Endocrine Society. More than 22,000 stakeholders — clinicians, researchers, patients, and advocacy groups — participated across surveys and international workshops.

The conclusion was unambiguous: the term “Polycystic Ovary Syndrome” was scientifically inaccurate on multiple counts.

What was wrong with “PCOS”?

• “Polycystic” — implies multiple pathological cysts on the ovaries. In reality, there is no increase in abnormal ovarian cysts. What appears on ultrasound are multiple small, immature follicles — a consequence of hormonal disruption, not structural disease.
• “Ovary Syndrome” — reduced the condition to a gynaecological disorder, when in truth it is a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological, and psychological health.

This linguistic inaccuracy had real clinical consequences: women were misunderstood by treating physicians, received incomplete treatment plans, and were left confused about their own diagnosis.

Decoding the New Name: What Does PMOS Mean?

The new name — Polyendocrine Metabolic Ovarian Syndrome — is a precise, evidence-based description of the condition’s true nature.

The Clinical Profile of PMOS: A Multisystem Condition

PMOS affects approximately 1 in 8 women globally — over 170 million individuals — yet up to 70% remain undiagnosed. It is not a disease of reproductive age alone; its metabolic consequences can persist throughout a woman’s lifetime.

1. Hormonal (Endocrine) Disruption

At its core, PMOS is a disorder of hormonal dysregulation involving multiple endocrine axes:

• Hyperandrogenism — elevated levels of androgens (testosterone, DHEAS, androstenedione) produced by the ovaries and adrenal glands
• Disrupted LH/FSH ratio — impaired signalling between the pituitary gland and the ovaries, leading to anovulation
• Abnormal neuroendocrine signalling — altered GnRH pulsatility, which drives the cascade of downstream hormonal imbalances

2. Metabolic Dysfunction

This is among the most clinically significant — and historically underappreciated — aspects of PMOS:

• Insulin resistance is present in up to 85% of women with PMOS, including 75% of lean women — a finding that challenges the outdated notion that PMOS primarily affects women who are overweight
• Compensatory hyperinsulinemia further stimulates ovarian androgen production, creating a self-perpetuating hormonal cycle
• Elevated risk of Type 2 Diabetes Mellitus, dyslipidaemia, and cardiovascular disease over the long term

3. Reproductive Consequences

• Oligo- or anovulation — infrequent or absent ovulation, directly impacting natural conception
• Menstrual irregularity — cycles longer than 35 days, absent periods, or unpredictable bleeding patterns
• Subfertility — PMOS is one of the most common causes of female infertility in reproductive-age women
• Polycystic ovarian morphology (PCOM) on ultrasound — follicle count ≥20 per ovary or ovarian volume >10 mL

4. Dermatological Manifestations

These are frequently the first signs that bring a woman to the clinic:

• Hirsutism — excess terminal hair growth along the face, chest, abdomen, and inner thighs
• Acne vulgaris — particularly cystic, hormonal acne affecting the jaw, chin, and neck
• Androgenic alopecia — diffuse scalp hair thinning
• Acanthosis nigricans — hyperpigmented, velvety skin patches at skin folds, a marker of insulin resistance

5. Psychological and Mental Health Impact

This dimension is often invisible in clinical consultations but carries profound significance:

• Significantly elevated rates of anxiety disorders and clinical depression
• Body image disturbance secondary to hirsutism, weight changes, and acne
• Emotional burden associated with infertility and repeated treatment cycles
• Social and occupational impact of a chronic, poorly understood condition

At CIFAR, we integrate psychological support as a standard component of PMOS management, recognising that emotional wellbeing is inseparable from reproductive health.

Diagnosis of PMOS: The Rotterdam Criteria

The diagnostic framework remains anchored in the Rotterdam Criteria (2003), requiring the presence of at least two of the following three features, after exclusion of other aetiologies:

1. Oligo- and/or anovulation — menstrual irregularity or absence of ovulation
2. Clinical or biochemical hyperandrogenism — physical signs or elevated serum androgen levels
3. Polycystic ovarian morphology (PCOM) — confirmed on transvaginal ultrasound

It is essential to rule out conditions that can mimic PMOS, including hypothyroidism, hyperprolactinaemia, congenital adrenal hyperplasia, and androgen-secreting tumours, before confirming the diagnosis.

What Changes Clinically with the PMOS Rename?

The name change carries significant implications beyond nomenclature:

1. Broader Diagnostic Lens Clinicians will now be prompted to evaluate metabolic and endocrine parameters routinely — not just reproductive ones. Fasting insulin, lipid profiles, and glucose tolerance testing should become standard at first presentation.

2. Multidisciplinary Treatment Planning PMOS demands a team approach: gynaecologist, reproductive endocrinologist, nutritionist, and where necessary, a psychologist or cardiologist. At CIFAR, this model has been our standard of practice since inception.

3. Reduced Diagnostic Delay With the name no longer anchored to “cysts,” physicians across specialties — endocrinologists, dermatologists, general practitioners — will be better equipped to identify and refer patients presenting with metabolic or dermatological features alone.

4. Improved Research and Policy Frameworks The rename will directly influence international disease classification systems (ICD), and the design of future clinical trials — ensuring the full spectrum of PMOS is studied and treated.

PMOS and Fertility: A Message to Women Trying to Conceive

PMOS is a leading — but treatable — cause of infertility. With a personalised, evidence-based approach, the vast majority of women with PMOS can achieve successful pregnancy outcomes.

At CIFAR, our treatment pathway for PMOS-related subfertility follows a stepwise, evidence-driven protocol:

• Lifestyle optimisation — Even a modest weight reduction of 5–10% in women with elevated BMI can restore ovulatory cycles and significantly improve IVF outcomes
• Metabolic correction — Insulin sensitisers such as Metformin form an important adjunct in selected patients, improving hormonal profiles and ovarian response
• Ovulation induction — Letrozole (aromatase inhibitor) is the current first-line agent; Clomiphene citrate and gonadotrophins are used in tailored protocols
• Intrauterine Insemination (IUI) — for women with patent fallopian tubes and adequate semen parameters
• IVF / ICSI — for cases where simpler interventions have not succeeded, or where additional male factor or tubal factor infertility coexists
• Freeze-all strategy in IVF — Given the elevated risk of Ovarian Hyperstimulation Syndrome (OHSS) in PMOS patients, a freeze-all embryo strategy with deferred frozen embryo transfer (FET) is frequently the safest approach
• Pre-implantation Genetic Testing (PGT) — available at CIFAR for selected cases to maximise implantation rates

Dr. Puneet Rana Arora’s Perspective

“In my clinical practice, I have always understood PCOS — now PMOS — as a condition far more complex than its old name suggested. The rename is a milestone, not just in terminology, but in how we think about women’s health. It demands that we treat the whole woman — her hormones, her metabolism, her mental health, and her dream of motherhood — not just her ovaries. At CIFAR, that has always been our approach, and we are proud to be part of a medical community that has finally caught up with science.”

A Three-Year Global Transition

The international community has committed to a structured three-year transition period, during which clinical guidelines, medical education curricula, and disease classification systems worldwide will be updated. At CIFAR, we have already adopted the PMOS terminology in all patient communications, clinical records, and educational materials.

Conclusion

The renaming of PCOS to PMOS is more than a change of initials. It is a formal acknowledgement by the global medical community that this condition has been misunderstood, underdiagnosed, and undertreated for too long. It places hormonal complexity and metabolic health at the centre of the conversation — where they have always belonged.

If you have been diagnosed with PCOS / PMOS, or suspect you may be experiencing its symptoms, we encourage you to seek a comprehensive evaluation. Early diagnosis, personalised care, and the right clinical team can make all the difference.

About CIFAR — Centre for Infertility & Assisted Reproduction

CIFAR is a NABH-accredited fertility centre located in Sector 27, Gurugram, Haryana, offering advanced reproductive medicine services to patients across India and internationally. Led by Dr. Puneet Rana Arora, CIFAR specialises in IVF, ICSI, IUI, fertility preservation, oncofertility, and the comprehensive management of PMOS and other causes of infertility.

📍 Plot No. 561P, 2nd & 3rd Floor, Sector 27, Gurugram, Haryana

📞 +91 9958009305 | +91 8826539305

✉️ helpdesk@cifarivf.com

🌐 www.cifarivf.com

This article is intended for informational and educational purposes. For personalised medical advice, please consult Dr. Puneet Rana Arora or a qualified reproductive medicine specialist.

https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change

https://www.pharmacytimes.com/view/polycystic-ovary-syndrome-undergoes-name-change-polyendocrine-metabolic-ovarian-syndrome